MX368931B - Animales no humanos que tienen un gen de proteina reguladora de señal humanizado. - Google Patents

Animales no humanos que tienen un gen de proteina reguladora de señal humanizado.

Info

Publication number
MX368931B
MX368931B MX2016003636A MX2016003636A MX368931B MX 368931 B MX368931 B MX 368931B MX 2016003636 A MX2016003636 A MX 2016003636A MX 2016003636 A MX2016003636 A MX 2016003636A MX 368931 B MX368931 B MX 368931B
Authority
MX
Mexico
Prior art keywords
human animals
regulatory protein
protein gene
humanized
sirpa
Prior art date
Application number
MX2016003636A
Other languages
English (en)
Spanish (es)
Other versions
MX2016003636A (es
Inventor
J Murphy Andrew
Gurer Cagan
Gavin Thurston O
Varghese Bindu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2016003636A publication Critical patent/MX2016003636A/es
Publication of MX368931B publication Critical patent/MX368931B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
MX2016003636A 2013-09-23 2014-09-23 Animales no humanos que tienen un gen de proteina reguladora de señal humanizado. MX368931B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881261P 2013-09-23 2013-09-23
PCT/US2014/056910 WO2015042557A1 (en) 2013-09-23 2014-09-23 Non-human animals having a humanized signal-regulatory protein gene

Publications (2)

Publication Number Publication Date
MX2016003636A MX2016003636A (es) 2016-07-21
MX368931B true MX368931B (es) 2019-10-22

Family

ID=51663510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003636A MX368931B (es) 2013-09-23 2014-09-23 Animales no humanos que tienen un gen de proteina reguladora de señal humanizado.

Country Status (28)

Country Link
US (9) US9193977B2 (https=)
EP (5) EP4635977A3 (https=)
JP (4) JP6453893B2 (https=)
KR (2) KR102407354B1 (https=)
CN (2) CN105592695B (https=)
AU (3) AU2014321187B2 (https=)
CA (1) CA2925564C (https=)
CY (1) CY1121410T1 (https=)
DK (4) DK2922394T3 (https=)
ES (4) ES2624614T3 (https=)
FI (2) FI4269430T3 (https=)
HR (3) HRP20251062T1 (https=)
HU (3) HUE042412T2 (https=)
IL (4) IL297607B2 (https=)
LT (3) LT3434101T (https=)
MX (1) MX368931B (https=)
NZ (1) NZ717817A (https=)
PH (1) PH12016500342A1 (https=)
PL (3) PL3434101T3 (https=)
PT (4) PT3175706T (https=)
RS (3) RS67091B1 (https=)
RU (2) RU2018136614A (https=)
SG (3) SG10201902547SA (https=)
SI (3) SI4269430T1 (https=)
SM (3) SMT202300287T1 (https=)
TR (1) TR201901782T4 (https=)
WO (1) WO2015042557A1 (https=)
ZA (1) ZA201601138B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2485583T (pt) 2009-10-06 2016-09-22 Univ Yale Ratinhos geneticamente modificados e enxerto
MX350385B (es) 2011-02-15 2017-09-04 Regeneron Pharma Ratones de m-csf humanizada.
IN2015DN02032A (https=) 2012-09-07 2015-08-14 Univ Yale
CA2887706C (en) 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
CN105592695B (zh) * 2013-09-23 2018-04-10 瑞泽恩制药公司 具有人源化信号调节蛋白基因的非人动物
ES2715949T3 (es) 2013-10-15 2019-06-07 Regeneron Pharma Animales con IL-15 humanizada
CA2929846C (en) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
HUE051088T2 (hu) 2014-04-08 2021-03-01 Regeneron Pharma Humanizált FC-gamma receptorokkal rendelkezõ nem humán élõlények
NO2785538T3 (https=) 2014-05-07 2018-08-04
SG10202002187WA (en) 2014-05-19 2020-04-29 Regeneron Pharma Genetically modified non-human animals expressing human epo
ES2783424T3 (es) 2014-06-19 2020-09-17 Regeneron Pharma Animales no humanos que tienen un gen de muerte celular programada 1 humanizado
RU2020122439A (ru) 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
SI3086637T1 (sl) 2014-12-05 2019-04-30 Regeneron Pharmaceuticals, Inc. Nehumane živali s humaniziranim označevalcem diferenciacije gena CD47
HUE052606T2 (hu) 2014-12-09 2021-05-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
KR102658190B1 (ko) * 2015-04-13 2024-04-17 리제너론 파마슈티칼스 인코포레이티드 인간화된 sirpa-il15 녹인 마우스 및 이의 이용 방법
CN104904661B (zh) * 2015-06-05 2018-07-24 杭州正因生物技术有限公司 一种人源化小鼠
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
SG11201803409UA (en) 2015-11-20 2018-05-30 Regeneron Pharma Non-human animals having a humanized lymphocyte-activation gene 3
MX2018009513A (es) 2016-02-04 2019-01-31 Regeneron Pharma Animales no humanos que tienen un gen angptl8 modificado genéticamente.
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
CN108467873B (zh) 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
WO2018177441A1 (en) 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα
CN108588126B (zh) 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Cd47基因人源化改造动物模型的制备方法及应用
WO2018233608A1 (en) * 2017-06-19 2018-12-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric cd28
CN109136261B (zh) 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化cd28基因改造动物模型的制备方法及应用
WO2019028032A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF
CN111182790A (zh) 2017-07-31 2020-05-19 瑞泽恩制药公司 Crispr报告体非人类动物及其用途
MX394999B (es) * 2017-09-29 2025-03-24 Regeneron Pharma Animales no humanos que comprenden un locus ttr humanizado y metodos de uso
IL310006A (en) 2017-11-30 2024-03-01 Regeneron Pharma Non-human animals containing a humanized TRKB locus
CN111885915B (zh) 2018-03-19 2023-04-28 瑞泽恩制药公司 使用crispr/cas系统对动物进行转录调制
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
KR20250079073A (ko) 2018-07-10 2025-06-04 고쿠리츠다이가쿠호진 고베다이가쿠 항 SIRPα 항체
IL278267B2 (en) 2018-07-16 2025-02-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020160285A1 (en) * 2019-02-01 2020-08-06 The Board Of Trustees Of The Leland Stanford Junior University SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION
ES2966625T3 (es) 2019-04-04 2024-04-23 Regeneron Pharma Roedores que comprenden un locus del factor de coagulación 12 humanizado
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
US11622547B2 (en) 2019-06-07 2023-04-11 Regeneran Pharmaceuticals, Inc. Genetically modified mouse that expresses human albumin
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
CN113122574A (zh) * 2019-12-31 2021-07-16 百奥赛图(北京)医药科技股份有限公司 一种免疫缺陷型人源化非人动物的构建方法
EP4096396A1 (en) 2020-01-28 2022-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
WO2021216505A1 (en) 2020-04-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cxcl13 gene
KR20230124973A (ko) * 2020-12-21 2023-08-28 리제너론 파마슈티칼스 인코포레이티드 인간화 tslp 유전자, 인간화 tslp 수용체 유전자, 및/또는인간화 il7ra 유전자를 갖는 비인간 동물
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
CN118632622A (zh) 2021-12-08 2024-09-10 瑞泽恩制药公司 突变型肌纤蛋白疾病模型及其用途
WO2023143341A1 (en) * 2022-01-25 2023-08-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric nkp46
IL318159A (en) 2022-07-19 2025-03-01 Regeneron Pharma Genetically modified animal model and its use to model the human immune system
WO2024073679A1 (en) 2022-09-29 2024-04-04 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
US20240415103A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2025250495A1 (en) 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149635A (en) * 1986-09-12 1992-09-22 Abbott Biotech, Inc. Messenger RNA stabilization in animal cells
SK3542000A3 (en) * 1997-09-12 2000-08-14 Apotech R & D Sa Nucleic acid coding ligand april, a vector, a host cell, method for preparing ligand april, a polypeptide of ligand april, a pharmaceutical composition and an antibody, and use thereof
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP4936899B2 (ja) * 2003-12-24 2012-05-23 ジー２ インフラメイション ピーティーワイ エルティーディー ヒトまたはヒト化Ｃ５ａＲをコードするポリヌクレオチドを含むトランスジェニック非ヒト哺乳動物
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
WO2006128163A2 (en) * 2005-05-27 2006-11-30 Memory Pharmaceuticals Corp. Transgenic alzheimer's mouse model vectors and uses thereof
US20070028316A1 (en) * 2005-06-02 2007-02-01 Xiaoxia Li Transgenic non-human Act1-deficient mammals and uses thereof
US20100239578A1 (en) * 2007-10-11 2010-09-23 University Health Network Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
PT2485583T (pt) 2009-10-06 2016-09-22 Univ Yale Ratinhos geneticamente modificados e enxerto
EP2618656B1 (en) * 2010-09-20 2018-06-20 Yale University, Inc. HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE
CN103492576A (zh) * 2011-02-14 2014-01-01 雷维维科公司 用于血管化异种移植物及其衍生物的异种移植的遗传修饰的猪
MX350385B (es) * 2011-02-15 2017-09-04 Regeneron Pharma Ratones de m-csf humanizada.
DK3590332T3 (da) 2011-10-28 2022-05-23 Regeneron Pharma Genmodificerede mus, der eksprimerer kimære major histokompatibilitetskompleks (MHC) II-molekyler
SI2770821T1 (en) 2011-10-28 2018-01-31 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex of mice
WO2013063556A1 (en) 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
IN2015DN02032A (https=) 2012-09-07 2015-08-14 Univ Yale
CA2887706C (en) 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
KR102714111B1 (ko) 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
PL2958937T3 (pl) 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej
CN105592695B (zh) 2013-09-23 2018-04-10 瑞泽恩制药公司 具有人源化信号调节蛋白基因的非人动物
CA2984413A1 (en) * 2015-04-30 2016-11-03 Institute Of Immunology Co., Ltd. Transgenic non-human animal expressing human specific molecule and human fc.gamma. receptor family

Also Published As

Publication number Publication date
US20150089678A1 (en) 2015-03-26
ES2959333T3 (es) 2024-02-23
HUE072332T2 (hu) 2025-11-28
EP2922394A1 (en) 2015-09-30
US10426146B2 (en) 2019-10-01
US10206379B2 (en) 2019-02-19
EP3434101B1 (en) 2023-08-16
EP3175706A1 (en) 2017-06-07
EP4635977A3 (en) 2026-01-21
PT3175706T (pt) 2019-02-11
RS64573B1 (sr) 2023-10-31
IL244187B (en) 2018-11-29
PT2922394T (pt) 2017-05-22
AU2020286187B2 (en) 2024-06-13
US9127292B2 (en) 2015-09-08
IL244187A0 (en) 2016-04-21
US20190124895A1 (en) 2019-05-02
PT3434101T (pt) 2023-09-19
FI4269430T3 (fi) 2025-08-08
ES3037239T3 (en) 2025-09-30
JP2021104064A (ja) 2021-07-26
AU2014321187B2 (en) 2020-09-17
SG11201601184UA (en) 2016-03-30
CN108441497A (zh) 2018-08-24
JP2019047818A (ja) 2019-03-28
US9700027B2 (en) 2017-07-11
EP4269430A3 (en) 2024-01-10
AU2020286187A1 (en) 2021-01-07
JP7149370B2 (ja) 2022-10-06
AU2024216527A1 (en) 2024-09-19
CN108441497B (zh) 2021-10-29
PL3175706T3 (pl) 2019-05-31
US9462794B2 (en) 2016-10-11
DK3434101T3 (da) 2023-10-02
ZA201601138B (en) 2020-06-24
US20200187468A1 (en) 2020-06-18
IL278679A (en) 2022-12-01
RU2016110462A (ru) 2017-10-30
EP3175706B1 (en) 2018-11-07
IL297607B2 (en) 2024-01-01
ES2624614T3 (es) 2017-07-17
HUE063376T2 (hu) 2024-01-28
EP4269430B1 (en) 2025-06-18
KR20160056900A (ko) 2016-05-20
SI3434101T1 (sl) 2023-11-30
KR102407354B1 (ko) 2022-06-10
KR20220032125A (ko) 2022-03-15
SMT201900067T1 (it) 2019-02-28
US20160050896A1 (en) 2016-02-25
RU2018136614A (ru) 2018-11-27
JP6665269B2 (ja) 2020-03-13
JP2020114209A (ja) 2020-07-30
EP4269430A2 (en) 2023-11-01
JP6875573B2 (ja) 2021-05-26
NZ717817A (en) 2022-07-01
PL3434101T3 (pl) 2024-02-19
SMT202300287T1 (it) 2023-11-13
LT3175706T (lt) 2019-02-25
MX2016003636A (es) 2016-07-21
US20150089679A1 (en) 2015-03-26
RU2671166C2 (ru) 2018-10-29
HK1209275A1 (en) 2016-04-01
US11019810B2 (en) 2021-06-01
SG10201801326PA (en) 2018-03-28
FI3434101T3 (fi) 2023-10-02
CY1121410T1 (el) 2020-05-29
IL278679B2 (en) 2023-04-01
US20170265442A1 (en) 2017-09-21
DK2922394T3 (en) 2017-05-15
US20160374321A1 (en) 2016-12-29
US20180139941A1 (en) 2018-05-24
US20210251201A1 (en) 2021-08-19
HUE042412T2 (hu) 2019-06-28
RU2016110462A3 (https=) 2018-03-30
CA2925564A1 (en) 2015-03-26
PL4269430T3 (pl) 2025-10-13
DK4269430T3 (da) 2025-08-18
SI4269430T1 (sl) 2025-09-30
RS67091B1 (sr) 2025-09-30
SI3175706T1 (sl) 2019-03-29
WO2015042557A1 (en) 2015-03-26
US12161097B2 (en) 2024-12-10
US9193977B2 (en) 2015-11-24
ES2710282T3 (es) 2019-04-24
WO2015042557A4 (en) 2015-06-18
DK3434101T5 (da) 2024-09-16
SMT202500280T1 (it) 2025-09-12
CN105592695B (zh) 2018-04-10
KR102370419B1 (ko) 2022-03-04
IL297607B1 (en) 2023-09-01
CA2925564C (en) 2023-03-21
EP3434101A1 (en) 2019-01-30
HRP20251062T1 (hr) 2025-11-07
HRP20231121T1 (hr) 2023-12-22
HRP20190227T1 (hr) 2019-06-14
IL297607A (en) 2022-12-01
TR201901782T4 (tr) 2019-03-21
EP4635977A2 (en) 2025-10-22
PT4269430T (pt) 2025-08-06
US9901083B2 (en) 2018-02-27
JP6453893B2 (ja) 2019-01-16
LT3434101T (lt) 2023-09-25
JP2016537015A (ja) 2016-12-01
CN105592695A (zh) 2016-05-18
IL262958A (en) 2018-12-31
LT4269430T (lt) 2025-08-25
PH12016500342A1 (en) 2016-05-02
DK3175706T3 (en) 2019-03-04
SG10201902547SA (en) 2019-04-29
RS58365B1 (sr) 2019-03-29
EP2922394B1 (en) 2017-02-22

Similar Documents

Publication Publication Date Title
PH12016500342A1 (en) Non-human animals having a humanized signal-regulatory protein gene
NZ769992A (en) Non-human animals having a humanized cluster of differentiation 47 gene
MX2016016903A (es) Animales no humanos que tienen un gen de muerte celular programada 1 humanizado.
MX2018005389A (es) Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado.
MY183188A (en) Non-human animals having a humanized b-cell activating factor gene
MY183189A (en) Non-human animals having a humanized a proliferation-inducing ligand gene
MX2017007636A (es) Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
PH12019501262A1 (en) Modified guide rnas
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
MX2017006802A (es) Animales no humanos que expresan el complejo cd3 humanizado.
PH12016502058A1 (en) Humanized il-4 and il-4r alpha animals
MY173936A (en) Humanized light chain mice field of invention
PH12016502162A1 (en) Multiplex gene editing in swine
MX2016014504A (es) Animales c5 y c3 humanizados.
EP4414988A3 (en) Methods, systems, and software for identifying bio-molecules using models of multiplicative form
MY164836A (en) Genetically modified major histocompatibility complex mice
MX355726B (es) Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii.
NZ703689A (en) Humanized non-human animals with restricted immunoglobulin heavy chain loci
MX2016004781A (es) Il-15 humanizada en animales.
PH12016502170A1 (en) Humanized dipeptidyl peptidase iv (dpp4) animals
MX2018009513A (es) Animales no humanos que tienen un gen angptl8 modificado genéticamente.
EP4285930A3 (en) Protein formulations
HK1244511A1 (zh) 与嗜酸细胞食管炎相关的基因改变的诊断和治疗

Legal Events

Date Code Title Description
FG Grant or registration